HEPA News and Press, Hepion Pharmaceuticals Inc. From 02/16/21

Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...

Hepion Pharmaceuticals (HEPA) plunges 26% premarket after pricing its public offering of 44.2M common shares at $2.00/share, for gross proceeds of $88.4M. Net proceeds will be used to fund R&D activities, as well as for working capital and other general corporate purpo...

bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...

EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the ...

Hepion Pharmaceuticals (HEPA) announces that it intends to offer to sell shares in an underwritten public offering.The company intends to use the net proceeds from the offering primarily for research and development and product development, among other things.ThinkEquity, a division of Fordha...

EDISON, NJ / ACCESSWIRE / February 12, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion Pharmaceuticals" or the "Company") today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sol...

Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...

Hepion Pharmaceuticals (HEPA) appoints Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer, effective February 16, 2021. Dr. Hobbs joins Hepion from Novo Nordisk. His 16 years of experience at Novo includes positions ranging from field medical affairs leadership at the...

EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver d...

EDISON, NJ / ACCESSWIRE / February 9, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver di...